Paul Later, MD
Neurology · Fort Wayne, INNPI 1689671166
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $91,104 of the $132,097 with a category attached, or 69.0%. 11 manufacturers reported payments, led by AbbVie at 57.9% of the total. Reporting peaked in 2021 at $45,831 and has fallen 54.0% since, to $21,088 in 2025. Among neurology clinicians in IN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 307 payments — averaging $430.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$77K
- Axsome Therapeutics, Inc.$16K
- Biohaven Pharmaceuticals, Inc.$15K
- Biogen$11K
- Pfizer$8K
- Biohaven Pharmaceutical Holding Company Ltd.$4K
- plus $3K from 5 others
Across 2 payments — averaging $1425.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$3K
What the payments were for
- Consulting fees$23,26018%
- Speaking & faculty fees$91,10469%
- Travel & lodging$11,3839%
- Food & beverage$5,8764%
- Education$4740%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 230 | $76,545 |
| Axsome Therapeutics, Inc. | 17 | $15,989 |
| Biohaven Pharmaceuticals, Inc. | 22 | $14,550 |
| Biogen | 12 | $10,761 |
| Pfizer | 9 | $7,638 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $3,875 |
| Argenx US, Inc. | 5 | $2,244 |
| AstraZeneca | 4 | $263 |
| W. L. Gore & Associates, Inc. | 1 | $143 |
| Johnson & Johnson | 3 | $59 |
| UCB, Inc. | 1 | $29 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$48,133
- NURTEC ODT$25,096
- Symbravo$15,552
- QULIPTA$9,799
- ADUHELM$2,228
- VYVGART$2,013
- TYSABRI$150
- GORE CARDIOFORM Septal Occluder$143
- ULTOMIRIS$129
- ZAVZPRET$108
How this compares
$132,097 in reported general payments places this provider in the 90th percentile of 308 neurology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Nurtec OdtRimegepant Sulfate | 73 | $147,530 |
| UbrelvyUbrogepant | 66 | $106,015 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 13 | $105,733 |
| Emgality PenGalcanezumab-Gnlm | 46 | $48,186 |
| Emgality SyringeGalcanezumab-Gnlm | 15 | $37,645 |
| QuliptaAtogepant | 27 | $36,054 |
| BriviactBrivaracetam | 19 | $27,156 |
| Ajovy SyringeFremanezumab-Vfrm | 15 | $18,195 |
| Lacosamide | 30 | $5,705 |
| Memantine Hcl | 184 | $5,544 |
| Rivastigmine | 12 | $4,537 |
| Levetiracetam | 136 | $3,898 |
| Pyridostigmine Bromide | 48 | $3,745 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 135 | $3,259 |
| Gabapentin | 161 | $3,118 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerNurtec Odt | $7,638 | $147,53073 claims |
| AbbVieUbrelvy, Qulipta | $76,545 | $142,07093 claims |
| UCB, Inc.Briviact | $29 | $27,15619 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 308 neurology providers in Indiana.
Other neurology in Fort Wayne
- Ajay GuptaFort Wayne$411K
- Marlene BultemeyerFort Wayne$277K
- Andrea HallerFort Wayne$242K
- Christopher VachonFort Wayne$27K
- William ConteMerrillville$1.2M
- Anthony SimchakLafayette$720K
- Mark JanickiLebanon$573K
- Roderick WarrenEvansville$296K
- Ender AkanMunster$296K
- Christopher WilsonAvon$283K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.